FDA Inspection 1244008 — Infar, S.A.

Infar, S.A. — FEI 3003144717

The FDA completed an inspection of Infar, S.A. on April 20, 2023 in Palafolls. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
April 20, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Palafolls (Spain)

Additional Details

Mutual Recognition Agreement (MRA)